Niagen Bioscience (NAGE) AI Stock Analysis

• Market Cap: $800.72M
• Dividend Yield: N/A
• Average Volume (3M): 1.19M
• Price to Earnings (P/E): 46.8
• Beta (1Y): 1.03
• Revenue Growth: 35.89%
• EPS Growth: N/A
• Country: US
• Employees: 104
• Sector: Healthcare
• Sector Strength: 47
• Industry: Biotechnology
• EPS (TTM): 0.04
• Shares Outstanding: 79,752,960
• 10 Day Avg. Volume: 831,199
• 30 Day Avg. Volume: 1,191,228
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 1.48
• Enterprise Value/Revenue: 10.19
• Enterprise Value/Gross Profit: 16.02
• Enterprise Value/Ebitda: 65.44
• 1Y Price Target: $14.64
• Price Target Upside: 50.00% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 5

• Rating: 73 Outperform
• Price Target: $11.00 ▲(12.70% Upside)

Niagen Bioscience's overall stock score reflects its strong financial performance and positive earnings call, which are the most significant factors. The company's strategic growth initiatives and improved profitability are promising. However, the high P/E ratio and mixed technical indicators suggest caution. Regulatory challenges and potential delays in study results also pose risks.

Positive Factors

Clinical Trials and Pharmaceutical Applications

Niagen's proprietary molecules are undergoing multiple clinical trials for various rare diseases and pharmaceutical applications that could further unlock additional value.

Product Innovation and Market Expansion

Niagen Bioscience continues to see growing consumer interest around boosting NAD+ levels to help with healthy aging and has been innovating ways to help consumers meet their needs.

Revenue and Earnings Performance

Niagen Bioscience's revenue and earnings have exceeded expectations, leading to an increased price target.

Negative Factors

Clinical Data and Legal Risks

Risks include slower-than-projected U.S. sales growth, unfavorable clinical data, and adverse legal decisions.

Sales Growth Risks

Risks to consider include slower-than-projected sales growth in the U.S. and potential adverse legal or geopolitical factors.

Niagen Bioscience Business Overview & Revenue Model

Company Description

Niagen Bioscience (NAGE) is a biotechnology company focused on the research, development, and commercialization of innovative health and wellness products. The company operates primarily within the nutraceuticals sector, specializing in the production of nicotinamide riboside (NR), a precursor to NAD+ (nicotinamide adenine dinucleotide). NR is associated with various health benefits, including cellular energy production, anti-aging effects, and improved metabolic health. Niagen's core products include dietary supplements aimed at enhancing cellular health and longevity, catering to a growing consumer demand for wellness-oriented solutions.

How the Company Makes Money

Niagen Bioscience generates revenue through the sale of its proprietary nicotinamide riboside products, which are marketed directly to consumers and through partnerships with various health and wellness retailers. The company employs a direct-to-consumer model via its online platform, leveraging e-commerce to reach a broad audience. Additionally, Niagen collaborates with third-party manufacturers and distributors to expand its market reach. Key revenue streams include retail sales, online sales, and potential licensing agreements for its patented NR technology. Ongoing research and development efforts aimed at discovering new applications for NR may also lead to future revenue opportunities through product diversification and partnerships with other biotech firms.

Niagen Bioscience Financial Statement Overview

Summary

Niagen Bioscience has shown remarkable financial improvement, transitioning from losses to profitability. Revenue growth and margin improvements are notable, supported by a strong balance sheet with low leverage. Cash flow generation is robust, enhancing financial flexibility. The company is well-positioned for future growth, though maintaining these trends will be crucial.

Income Statement

Niagen Bioscience has shown impressive revenue growth, with a 19.17% increase from 2023 to 2024. The gross profit margin improved to 61.83% in 2024, indicating strong cost management. The company turned profitable in 2024 with a net profit margin of 8.59%, a significant improvement from previous losses. EBIT and EBITDA margins also turned positive, reflecting operational efficiency gains.

Balance Sheet

The balance sheet is robust, with a low debt-to-equity ratio of 0.06, indicating minimal leverage. The equity ratio stands at 67.52%, showcasing a strong equity base. Return on equity improved significantly to 18.55% in 2024, highlighting effective use of equity to generate profits.

Cash Flow

Cash flow performance is strong, with a 71.43% increase in free cash flow from 2023 to 2024. The operating cash flow to net income ratio is 1.42, indicating healthy cash generation relative to profits. The free cash flow to net income ratio is 1.40, demonstrating efficient cash conversion.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	116.30M	99.60M	83.57M	72.05M	67.45M	59.26M
Gross Profit	73.99M	61.59M	50.78M	42.80M	41.49M	35.27M
EBITDA	18.12M	9.21M	-3.89M	-16.74M	-25.45M	-18.34M
Net Income	17.73M	8.55M	-4.94M	-16.54M	-27.13M	-19.93M
Balance Sheet
Total Assets	91.53M	68.28M	54.96M	54.06M	57.84M	38.36M
Cash, Cash Equivalents and Short-Term Investments	60.32M	44.51M	27.17M	20.29M	28.02M	16.50M
Total Debt	3.29M	2.65M	3.28M	4.26M	4.70M	1.64M
Total Liabilities	27.33M	22.18M	26.51M	25.39M	26.11M	21.93M
Stockholders Equity	64.19M	46.09M	28.46M	28.67M	31.73M	16.42M
Cash Flow
Free Cash Flow	20.93M	11.95M	6.97M	-15.43M	-24.57M	-10.74M
Operating Cash Flow	21.21M	12.11M	7.12M	-15.10M	-24.16M	-10.60M
Investing Cash Flow	-257.00K	-143.00K	-143.00K	-334.00K	-409.00K	-165.00K
Financing Cash Flow	11.63M	5.37M	-90.00K	7.65M	36.09M	8.65M

Niagen Bioscience Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 9.76
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NAGE, the sentiment is Negative. The current price of 9.76 is above the 20-day moving average (MA) of 9.74, below the 50-day MA of 10.96, and above the 200-day MA of 8.29, indicating a neutral trend. The MACD of -0.17 indicates Negative momentum. The RSI at 45.34 is Neutral, neither overbought nor oversold. The STOCH value of 53.09 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for NAGE.

Niagen Bioscience Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NAGE	73 Outperform	$800.72M	46.76	37.36%	―	35.89%	―
Sector *	51 Neutral	$7.83B	-0.18	-40.10%	2.29%	21.46%	-2.03%
SVA	50 Neutral	$460.27M	―	-1.44%	―	―	―
BCYC	45 Neutral	$484.09M	―	-31.58%	―	-51.13%	7.57%
MRVI	44 Neutral	$617.98M	―	-55.41%	―	-22.52%	-37.00%
OPT	39 Underperform	$481.10M	―		―	-25.10%	-7.06%
SANA	33 Underperform	$833.02M	―	-109.12%	―	―	7.58%

Niagen Bioscience Corporate Events

Niagen Bioscience Reports Strong Q2 Sales Growth

On August 6, 2025, Niagen Bioscience reported a 37% increase in net sales to $31.1 million for the second quarter of 2025, with a net income of $3.6 million. The company also raised its full-year revenue outlook, expecting growth between 22% and 27%, driven by strong sales of Tru Niagen® and Niagen® ingredients. Recent operational highlights include the completion of the Phase III NOPARK trial for Parkinson’s disease and a partnership with Haukeland University Hospital. The company also expanded its presence in luxury hospitality and wellness clinics, reflecting its strategic focus on growth and innovation in the NAD+ market.

Niagen Bioscience Subsidiary Signs Supply Agreement

On July 25, 2025, ChromaDex, Inc., a subsidiary of Niagen Bioscience, signed a Supply Agreement with W. R. Grace & Co.-Conn, effective April 1, 2025, for the exclusive supply of Nicotinamide-beta-Riboside Chloride (NRCL). The agreement, which runs until April 30, 2029, includes provisions for automatic renewal and requires ChromaDex to purchase a minimum quantity of NRCL annually. The agreement also outlines a potential future License Agreement for ChromaDex to manufacture NRCL, though its execution is not guaranteed.

Niagen Bioscience Approves Equity Plan Amendment

At the Annual Meeting of Stockholders on June 24, 2025, Niagen Bioscience‘s shareholders approved an amendment to the 2017 Equity Incentive Plan, increasing the available shares by 4.75 million. Additionally, the Employee Stock Purchase Plan was approved, allowing employees to purchase shares at a discounted rate. These decisions are expected to enhance employee engagement and align stakeholder interests with the company’s growth objectives.